Eloxx Pharmaceuticals, Inc. quarterly report, Q3 FY2012

Filing identity and reporting period

Important discrepancy: The supplied filing is Senesco Technologies, Inc.’s Form 10-Q for the quarter and nine months ended March 31, 2012, filed May 14, 2012. It is not identified as an Eloxx Pharmaceuticals, Inc. filing or as a 2011 Q3 report. The summary below reflects the filing text provided.

Senesco describes itself as a development-stage biotechnology company pursuing human therapeutic applications of its gene technology and licensing agricultural applications.

Financial results and liquidity

The nine-month revenue was an agricultural-license milestone payment; the filing reports no revenue for the March quarter. Gross margin is not presented, and with no quarterly revenue, a meaningful quarterly margin is not available. Research and development expense was $1.926 million for nine months, down 38.6% from $3.135 million; general and administrative expense was $2.119 million, up 9.1% from $1.943 million.

At March 31, 2012, cash and cash equivalents were $3.207 million, working capital was approximately $1.410 million, and total assets were $8.635 million. Current liabilities were $3.533 million, including a $2.199 million line of credit; total liabilities were $4.036 million. The line of credit bears interest at the broker rate plus 2% (3.75% broker rate at March 31) and is secured by assets of a board member, not company assets.

Cash declined by $403,000 over the nine months, from $3.610 million at June 30, 2011. Financing cash included $3.219 million from common-stock and warrant issuance, including ATM sales. In January and March 2012, the company raised $2.862 million gross through common-stock sales and related warrants. The company issued 14.1 million additional common shares during the nine months; common shares outstanding were 91.9 million at March 31.

Changes versus prior comparable periods

• Quarterly net loss improved by $344,000, or 24.5%, from $1.405 million in 2011. R&D costs declined, while warrant fair-value income increased.
• Nine-month net loss improved by $930,000, or 20.4%, from $4.557 million in 2011. The filing attributes this primarily to the $200,000 milestone revenue and lower R&D spending, partly offset by higher G&A and lower non-operating income.
• The nine-month warrant-liability fair-value gain was $308,000, versus $453,000 in 2011. This noncash gain reduced reported loss.
• Cash used in operations improved to $3.278 million from $4.368 million in the prior-year nine-month period, while financing cash rose to $3.219 million from $1.639 million.

Outlook, developments, and risks

• Management estimated March 31 cash would fund operations through November 2012. It expected continued losses for several years and said it could not predict when, if ever, profitability would be achieved. Additional capital was expected to be needed; possible sources included equity or debt, the ATM, unused credit, licensing milestones, and new licenses. Availability and terms were not assured.
• SNS01-T was in an open-label Phase 1b/2a dose-escalation study in relapsed or refractory multiple myeloma patients. The company reported that patient treatment had begun. The filing also describes preclinical findings, which do not establish clinical efficacy.
• The December 2011 Rahan agreement changed a jointly funded banana-development arrangement to a license with mid- to upper-single-digit royalties on defined incremental revenue, without future company development-cost payments. A February 2012 BioCorp Ventures agreement covered evaluation of the technology for biofuel applications and contemplated license payments, royalties, and a 15% equity interest after the evaluation phase.
• Senesco warned that it depended on external financing, outsourced R&D, third-party licensees and partners, and a single principal technology platform. Clinical, regulatory, commercialization, patent, manufacturing, and consumer-acceptance risks could delay or prevent revenue.
• The company reported it did not meet the NYSE Amex $6 million minimum-net-worth continued-listing requirement. The exchange accepted its compliance plan and extended the period to regain compliance through July 20, 2012; failure could lead to delisting and reduced trading liquidity.
• Management said disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter. The filing reported no legal proceedings and no off-balance-sheet arrangements.

Most important facts to verify

1. Confirm the requested issuer and period: the supplied document is Senesco’s March 31, 2012 10-Q, not an Eloxx Pharmaceuticals 2011 Q3 filing.
2. Verify the cash runway estimate through November 2012 against subsequent financing, spending, and operating developments.
3. Review the terms and potential dilution from the 2012 equity and warrant offerings, ATM sales, preferred-stock conversion, and outstanding options and warrants.
4. Check the NYSE Amex compliance outcome and whether the company regained the required net worth by the stated deadline.
5. Track Phase 1b/2a SNS01-T enrollment, safety, and clinical results separately from the preclinical evidence described in the filing.